ArticleAmerican journal of translational research2025
Conbercept combined with retinal photocoagulation significantly improves visual acuity and quality of life in patients with proliferative diabetic retinopathy.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical efficacy of Conbercept combined with pars plana vitrectomy for proliferative diabetic retinopathy.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the clinical efficacy of Conbercept combined with retinal photocoagulation in patients with proliferative diabetic retinopathy (PDR) and its effect on visual acuity and related outcomes.
methodsThis retrospective study included 120 PDR patients treated between January 2019 and January 2021. Based on treatment modality, patients were assigned to a study group (SG, n=60; Conbercept combined with retinal photocoagulation) or a control group (CG, n=60; retinal photocoagulation alone). Surgical data, best-corrected visual acuity (BCVA), central macular thickness (CMT), frequency of Conbercept injections, incidence of postoperative complications, quality of life (QoL) scores, and the need for additional pan-retinal photocoagulation (PRP) were compared between the two groups. Multivariate logistic regression was performed to identify independent risk factors associated with surgical complications.
resultsCompared to the CG, the SG demonstrated significantly reduced intraoperative bleeding and greater improvements in BCVA and CMT from 1-48 months postoperatively (
conclusionThe combination of Conbercept with retinal photocoagulation significantly improved visual outcomes and reduced postoperative complications in PDR patients, particularly beneficial for patients with advanced age, prolonged disease duration, elevated HbA1c, extended surgical duration, or intraoperative bleeding.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.